# Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

> **NCT01748500** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 21 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Pantoprazole

## Key facts

- **NCT ID:** NCT01748500
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01748500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01748500, "Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01748500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*